Pediatrix Medical Group, Inc. (MD) Stock Competitors & Peer Comparison
See (MD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MD | $22.37 | +2.43% | 1.8B | 10.86 | $2.06 | N/A |
| HCA | $361.83 | -0.39% | 80.3B | 12.47 | $29.02 | +0.81% |
| SOLV | $82.42 | +5.18% | 14.3B | 10.09 | $8.17 | N/A |
| THC | $161.37 | -2.11% | 13.9B | 8.38 | $19.24 | N/A |
| DVA | $192.17 | -1.47% | 12.3B | 18.50 | $10.38 | N/A |
| FMS | $21.93 | +4.93% | 11.8B | 11.54 | $1.90 | +3.96% |
| EHC | $99.84 | -3.23% | 9.9B | 17.10 | $5.84 | +0.74% |
| ENSG | $164.29 | -1.43% | 9.6B | 26.71 | $6.15 | +0.16% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| UHS | $142.72 | -2.23% | 8.9B | 5.96 | $23.95 | +0.56% |
Stock Comparison
MD vs HCA Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, HCA has a market cap of 80.3B. Regarding current trading prices, MD is priced at $22.37, while HCA trades at $361.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas HCA's P/E ratio is 12.47. In terms of profitability, MD's ROE is +0.20%, compared to HCA's ROE of -1.23%. Regarding short-term risk, MD is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check HCA's competition here
MD vs SOLV Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, SOLV has a market cap of 14.3B. Regarding current trading prices, MD is priced at $22.37, while SOLV trades at $82.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas SOLV's P/E ratio is 10.09. In terms of profitability, MD's ROE is +0.20%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, MD is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check SOLV's competition here
MD vs THC Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, THC has a market cap of 13.9B. Regarding current trading prices, MD is priced at $22.37, while THC trades at $161.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas THC's P/E ratio is 8.38. In terms of profitability, MD's ROE is +0.20%, compared to THC's ROE of +0.41%. Regarding short-term risk, MD is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check THC's competition here
MD vs DVA Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, DVA has a market cap of 12.3B. Regarding current trading prices, MD is priced at $22.37, while DVA trades at $192.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas DVA's P/E ratio is 18.50. In terms of profitability, MD's ROE is +0.20%, compared to DVA's ROE of -1.33%. Regarding short-term risk, MD is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check DVA's competition here
MD vs FMS Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, FMS has a market cap of 11.8B. Regarding current trading prices, MD is priced at $22.37, while FMS trades at $21.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas FMS's P/E ratio is 11.54. In terms of profitability, MD's ROE is +0.20%, compared to FMS's ROE of +0.07%. Regarding short-term risk, MD is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check FMS's competition here
MD vs EHC Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, EHC has a market cap of 9.9B. Regarding current trading prices, MD is priced at $22.37, while EHC trades at $99.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas EHC's P/E ratio is 17.10. In terms of profitability, MD's ROE is +0.20%, compared to EHC's ROE of +0.25%. Regarding short-term risk, MD is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check EHC's competition here
MD vs ENSG Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, ENSG has a market cap of 9.6B. Regarding current trading prices, MD is priced at $22.37, while ENSG trades at $164.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas ENSG's P/E ratio is 26.71. In terms of profitability, MD's ROE is +0.20%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, MD is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check ENSG's competition here
MD vs OSH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, MD is priced at $22.37, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas OSH's P/E ratio is -17.65. In terms of profitability, MD's ROE is +0.20%, compared to OSH's ROE of +4.64%. Regarding short-term risk, MD is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check OSH's competition here
MD vs UHS Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, UHS has a market cap of 8.9B. Regarding current trading prices, MD is priced at $22.37, while UHS trades at $142.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas UHS's P/E ratio is 5.96. In terms of profitability, MD's ROE is +0.20%, compared to UHS's ROE of +0.21%. Regarding short-term risk, MD is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check UHS's competition here
MD vs CHE Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CHE has a market cap of 5.7B. Regarding current trading prices, MD is priced at $22.37, while CHE trades at $432.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CHE's P/E ratio is 23.60. In terms of profitability, MD's ROE is +0.20%, compared to CHE's ROE of +0.25%. Regarding short-term risk, MD is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check CHE's competition here
MD vs LHCG Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, MD is priced at $22.37, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas LHCG's P/E ratio is 82.83. In terms of profitability, MD's ROE is +0.20%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, MD is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check LHCG's competition here
MD vs MMED Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, MMED has a market cap of 3.9B. Regarding current trading prices, MD is priced at $22.37, while MMED trades at $14.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas MMED's P/E ratio is -11.07. In terms of profitability, MD's ROE is +0.20%, compared to MMED's ROE of -0.09%. Regarding short-term risk, MD is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check MMED's competition here
MD vs AMED Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, MD is priced at $22.37, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AMED's P/E ratio is 39.30. In terms of profitability, MD's ROE is +0.20%, compared to AMED's ROE of +0.09%. Regarding short-term risk, MD is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check AMED's competition here
MD vs OPCH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, OPCH has a market cap of 3.2B. Regarding current trading prices, MD is priced at $22.37, while OPCH trades at $20.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas OPCH's P/E ratio is 15.68. In terms of profitability, MD's ROE is +0.20%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, MD is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check OPCH's competition here
MD vs LFST Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, LFST has a market cap of 3B. Regarding current trading prices, MD is priced at $22.37, while LFST trades at $7.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas LFST's P/E ratio is 127.33. In terms of profitability, MD's ROE is +0.20%, compared to LFST's ROE of +0.02%. Regarding short-term risk, MD is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check LFST's competition here
MD vs NHC Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, NHC has a market cap of 2.9B. Regarding current trading prices, MD is priced at $22.37, while NHC trades at $188.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas NHC's P/E ratio is 23.80. In terms of profitability, MD's ROE is +0.20%, compared to NHC's ROE of +0.12%. Regarding short-term risk, MD and NHC have similar daily volatility (2.66).Check NHC's competition here
MD vs BKD Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, BKD has a market cap of 2.8B. Regarding current trading prices, MD is priced at $22.37, while BKD trades at $11.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas BKD's P/E ratio is -13.67. In terms of profitability, MD's ROE is +0.20%, compared to BKD's ROE of +401.19%. Regarding short-term risk, MD is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check BKD's competition here
MD vs ACHC Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, ACHC has a market cap of 2.3B. Regarding current trading prices, MD is priced at $22.37, while ACHC trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas ACHC's P/E ratio is -2.07. In terms of profitability, MD's ROE is +0.20%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, MD is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check ACHC's competition here
MD vs SEM Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, MD is priced at $22.37, while SEM trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas SEM's P/E ratio is 15.42. In terms of profitability, MD's ROE is +0.20%, compared to SEM's ROE of +0.08%. Regarding short-term risk, MD is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check SEM's competition here
MD vs ASTH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, MD is priced at $22.37, while ASTH trades at $37.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas ASTH's P/E ratio is 62.05. In terms of profitability, MD's ROE is +0.20%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, MD is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check ASTH's competition here
MD vs AMEH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, MD is priced at $22.37, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AMEH's P/E ratio is 39.25. In terms of profitability, MD's ROE is +0.20%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, MD is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AMEH's competition here
MD vs SGRY Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, MD is priced at $22.37, while SGRY trades at $13.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas SGRY's P/E ratio is -23.19. In terms of profitability, MD's ROE is +0.20%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, MD is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check SGRY's competition here
MD vs ADUS Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, MD is priced at $22.37, while ADUS trades at $89.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas ADUS's P/E ratio is 16.55. In terms of profitability, MD's ROE is +0.20%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, MD is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check ADUS's competition here
MD vs AGL Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, MD is priced at $22.37, while AGL trades at $95.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AGL's P/E ratio is -4.22. In terms of profitability, MD's ROE is +0.20%, compared to AGL's ROE of -1.46%. Regarding short-term risk, MD is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AGL's competition here
MD vs AVAH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AVAH has a market cap of 1.4B. Regarding current trading prices, MD is priced at $22.37, while AVAH trades at $6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AVAH's P/E ratio is 5.48. In terms of profitability, MD's ROE is +0.20%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, MD is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AVAH's competition here
MD vs HCSG Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, MD is priced at $22.37, while HCSG trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas HCSG's P/E ratio is 21.51. In terms of profitability, MD's ROE is +0.20%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, MD is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check HCSG's competition here
MD vs CMPS Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CMPS has a market cap of 1.3B. Regarding current trading prices, MD is priced at $22.37, while CMPS trades at $13.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CMPS's P/E ratio is -4.16. In terms of profitability, MD's ROE is +0.20%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, MD is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check CMPS's competition here
MD vs BKDT Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, MD is priced at $22.37, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas BKDT's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, MD is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check BKDT's competition here
MD vs ARDT Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, ARDT has a market cap of 1.2B. Regarding current trading prices, MD is priced at $22.37, while ARDT trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas ARDT's P/E ratio is 9.14. In terms of profitability, MD's ROE is +0.20%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, MD is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check ARDT's competition here
MD vs AMN Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AMN has a market cap of 1.2B. Regarding current trading prices, MD is priced at $22.37, while AMN trades at $30.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AMN's P/E ratio is -35.59. In terms of profitability, MD's ROE is +0.20%, compared to AMN's ROE of -0.05%. Regarding short-term risk, MD is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AMN's competition here
MD vs PNTG Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, PNTG has a market cap of 1B. Regarding current trading prices, MD is priced at $22.37, while PNTG trades at $30.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas PNTG's P/E ratio is 35.02. In terms of profitability, MD's ROE is +0.20%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, MD is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check PNTG's competition here
MD vs INNV Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, INNV has a market cap of 977.3M. Regarding current trading prices, MD is priced at $22.37, while INNV trades at $7.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas INNV's P/E ratio is -90.00. In terms of profitability, MD's ROE is +0.20%, compared to INNV's ROE of -0.09%. Regarding short-term risk, MD is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check INNV's competition here
MD vs USPH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, USPH has a market cap of 940.4M. Regarding current trading prices, MD is priced at $22.37, while USPH trades at $61.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas USPH's P/E ratio is 123.58. In terms of profitability, MD's ROE is +0.20%, compared to USPH's ROE of +0.00%. Regarding short-term risk, MD is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check USPH's competition here
MD vs TALK Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, TALK has a market cap of 871.1M. Regarding current trading prices, MD is priced at $22.37, while TALK trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas TALK's P/E ratio is 130.00. In terms of profitability, MD's ROE is +0.20%, compared to TALK's ROE of +0.01%. Regarding short-term risk, MD is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check TALK's competition here
MD vs FSHCX Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, FSHCX has a market cap of 825.5M. Regarding current trading prices, MD is priced at $22.37, while FSHCX trades at $108.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas FSHCX's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to FSHCX's ROE of N/A. Regarding short-term risk, MD is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check FSHCX's competition here
MD vs EHAB Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, MD is priced at $22.37, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas EHAB's P/E ratio is -197.14. In terms of profitability, MD's ROE is +0.20%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, MD is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check EHAB's competition here
MD vs SNDA Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, SNDA has a market cap of 663.2M. Regarding current trading prices, MD is priced at $22.37, while SNDA trades at $33.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas SNDA's P/E ratio is -5.68. In terms of profitability, MD's ROE is +0.20%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, MD is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check SNDA's competition here
MD vs GMRS Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, GMRS has a market cap of 501M. Regarding current trading prices, MD is priced at $22.37, while GMRS trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas GMRS's P/E ratio is 5.69. In terms of profitability, MD's ROE is +0.20%, compared to GMRS's ROE of N/A. Regarding short-term risk, MD is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check GMRS's competition here
MD vs TOI Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, TOI has a market cap of 473.9M. Regarding current trading prices, MD is priced at $22.37, while TOI trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas TOI's P/E ratio is -13.54. In terms of profitability, MD's ROE is +0.20%, compared to TOI's ROE of +3.27%. Regarding short-term risk, MD is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check TOI's competition here
MD vs MCTA Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, MD is priced at $22.37, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas MCTA's P/E ratio is 419.36. In terms of profitability, MD's ROE is +0.20%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, MD is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check MCTA's competition here
MD vs CCRN Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CCRN has a market cap of 426.5M. Regarding current trading prices, MD is priced at $22.37, while CCRN trades at $13.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CCRN's P/E ratio is -4.32. In terms of profitability, MD's ROE is +0.20%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, MD is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check CCRN's competition here
MD vs AIRS Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AIRS has a market cap of 402.8M. Regarding current trading prices, MD is priced at $22.37, while AIRS trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AIRS's P/E ratio is -33.59. In terms of profitability, MD's ROE is +0.20%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, MD is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AIRS's competition here
MD vs CYH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CYH has a market cap of 392.5M. Regarding current trading prices, MD is priced at $22.37, while CYH trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CYH's P/E ratio is 0.81. In terms of profitability, MD's ROE is +0.20%, compared to CYH's ROE of +0.06%. Regarding short-term risk, MD is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check CYH's competition here
MD vs AUNA Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AUNA has a market cap of 334.6M. Regarding current trading prices, MD is priced at $22.37, while AUNA trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AUNA's P/E ratio is 16.74. In terms of profitability, MD's ROE is +0.20%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, MD is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AUNA's competition here
MD vs AONC Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AONC has a market cap of 292.5M. Regarding current trading prices, MD is priced at $22.37, while AONC trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AONC's P/E ratio is -11.24. In terms of profitability, MD's ROE is +0.20%, compared to AONC's ROE of +0.06%. Regarding short-term risk, MD is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check AONC's competition here
MD vs CSU Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, MD is priced at $22.37, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CSU's P/E ratio is 0.67. In terms of profitability, MD's ROE is +0.20%, compared to CSU's ROE of -0.51%. Regarding short-term risk, MD is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check CSU's competition here
MD vs JYNT Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, JYNT has a market cap of 117.3M. Regarding current trading prices, MD is priced at $22.37, while JYNT trades at $8.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas JYNT's P/E ratio is 91.44. In terms of profitability, MD's ROE is +0.20%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, MD is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check JYNT's competition here
MD vs NAKAW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, MD is priced at $22.37, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas NAKAW's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, MD is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check NAKAW's competition here
MD vs BTMD Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, BTMD has a market cap of 104.1M. Regarding current trading prices, MD is priced at $22.37, while BTMD trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas BTMD's P/E ratio is 5.49. In terms of profitability, MD's ROE is +0.20%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, MD is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check BTMD's competition here
MD vs FVE Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, MD is priced at $22.37, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas FVE's P/E ratio is -5.64. In terms of profitability, MD's ROE is +0.20%, compared to FVE's ROE of -0.15%. Regarding short-term risk, MD is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check FVE's competition here
MD vs KDLYW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, MD is priced at $22.37, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas KDLYW's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, MD is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check KDLYW's competition here
MD vs DCGO Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, DCGO has a market cap of 56.3M. Regarding current trading prices, MD is priced at $22.37, while DCGO trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas DCGO's P/E ratio is -0.30. In terms of profitability, MD's ROE is +0.20%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, MD is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check DCGO's competition here
MD vs ALR Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, MD is priced at $22.37, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas ALR's P/E ratio is -1.11. In terms of profitability, MD's ROE is +0.20%, compared to ALR's ROE of -0.15%. Regarding short-term risk, MD is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check ALR's competition here
MD vs PIII Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, PIII has a market cap of 37.1M. Regarding current trading prices, MD is priced at $22.37, while PIII trades at $11.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas PIII's P/E ratio is -0.29. In terms of profitability, MD's ROE is +0.20%, compared to PIII's ROE of +1.85%. Regarding short-term risk, MD is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check PIII's competition here
MD vs IMAC Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, MD is priced at $22.37, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas IMAC's P/E ratio is -2.27. In terms of profitability, MD's ROE is +0.20%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, MD is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check IMAC's competition here
MD vs CCEL Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CCEL has a market cap of 28.2M. Regarding current trading prices, MD is priced at $22.37, while CCEL trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CCEL's P/E ratio is -10.94. In terms of profitability, MD's ROE is +0.20%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, MD is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check CCEL's competition here
MD vs CANO-WT Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, MD is priced at $22.37, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, MD is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check CANO-WT's competition here
MD vs AIH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, MD is priced at $22.37, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AIH's P/E ratio is -2.78. In terms of profitability, MD's ROE is +0.20%, compared to AIH's ROE of +1.16%. Regarding short-term risk, MD is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AIH's competition here
MD vs CANO Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, MD is priced at $22.37, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CANO's P/E ratio is -0.01. In terms of profitability, MD's ROE is +0.20%, compared to CANO's ROE of -1.49%. Regarding short-term risk, MD is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check CANO's competition here
MD vs FTRP Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, MD is priced at $22.37, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas FTRP's P/E ratio is -1.22. In terms of profitability, MD's ROE is +0.20%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, MD is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check FTRP's competition here
MD vs AMS Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AMS has a market cap of 9.2M. Regarding current trading prices, MD is priced at $22.37, while AMS trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AMS's P/E ratio is -6.32. In terms of profitability, MD's ROE is +0.20%, compared to AMS's ROE of -0.06%. Regarding short-term risk, MD is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AMS's competition here
MD vs MODV Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, MD is priced at $22.37, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas MODV's P/E ratio is -0.03. In terms of profitability, MD's ROE is +0.20%, compared to MODV's ROE of +1.84%. Regarding short-term risk, MD is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check MODV's competition here
MD vs SYRA Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, SYRA has a market cap of 5.8M. Regarding current trading prices, MD is priced at $22.37, while SYRA trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas SYRA's P/E ratio is -25.50. In terms of profitability, MD's ROE is +0.20%, compared to SYRA's ROE of -0.08%. Regarding short-term risk, MD is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check SYRA's competition here
MD vs GBNH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, MD is priced at $22.37, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas GBNH's P/E ratio is -0.06. In terms of profitability, MD's ROE is +0.20%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, MD is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check GBNH's competition here
MD vs RHE-PA Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, MD is priced at $22.37, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, MD's ROE is +0.20%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, MD is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check RHE-PA's competition here
MD vs RHE Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, MD is priced at $22.37, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas RHE's P/E ratio is -1.79. In terms of profitability, MD's ROE is +0.20%, compared to RHE's ROE of -0.36%. Regarding short-term risk, MD is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check RHE's competition here
MD vs TOIIW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, TOIIW has a market cap of 4.9M. Regarding current trading prices, MD is priced at $22.37, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas TOIIW's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, MD is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check TOIIW's competition here
MD vs ATIP Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, MD is priced at $22.37, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas ATIP's P/E ratio is -0.03. In terms of profitability, MD's ROE is +0.20%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, MD is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check ATIP's competition here
MD vs IMACW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, MD is priced at $22.37, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas IMACW's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, MD is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check IMACW's competition here
MD vs CCM Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, CCM has a market cap of 708.4K. Regarding current trading prices, MD is priced at $22.37, while CCM trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas CCM's P/E ratio is -1.54. In terms of profitability, MD's ROE is +0.20%, compared to CCM's ROE of +0.07%. Regarding short-term risk, MD is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check CCM's competition here
MD vs MNDR Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, MNDR has a market cap of 637.7K. Regarding current trading prices, MD is priced at $22.37, while MNDR trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas MNDR's P/E ratio is -0.30. In terms of profitability, MD's ROE is +0.20%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, MD is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check MNDR's competition here
MD vs TALKW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, TALKW has a market cap of 519.3K. Regarding current trading prices, MD is priced at $22.37, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas TALKW's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, MD is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check TALKW's competition here
MD vs NVOS Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, NVOS has a market cap of 394.6K. Regarding current trading prices, MD is priced at $22.37, while NVOS trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas NVOS's P/E ratio is -0.02. In terms of profitability, MD's ROE is +0.20%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, MD is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check NVOS's competition here
MD vs NIVF Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, NIVF has a market cap of 380.9K. Regarding current trading prices, MD is priced at $22.37, while NIVF trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas NIVF's P/E ratio is 0.02. In terms of profitability, MD's ROE is +0.20%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, MD is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check NIVF's competition here
MD vs BACK Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, BACK has a market cap of 172.9K. Regarding current trading prices, MD is priced at $22.37, while BACK trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas BACK's P/E ratio is -0.02. In terms of profitability, MD's ROE is +0.20%, compared to BACK's ROE of +1.05%. Regarding short-term risk, MD is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check BACK's competition here
MD vs PIIIW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, PIIIW has a market cap of 57.5K. Regarding current trading prices, MD is priced at $22.37, while PIIIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, MD's ROE is +0.20%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, MD is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check PIIIW's competition here
MD vs NIVFW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, NIVFW has a market cap of 44.6K. Regarding current trading prices, MD is priced at $22.37, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas NIVFW's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, MD is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check NIVFW's competition here
MD vs IONM Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, IONM has a market cap of 313. Regarding current trading prices, MD is priced at $22.37, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas IONM's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to IONM's ROE of +5.28%. Regarding short-term risk, MD is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check IONM's competition here
MD vs KND Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, KND has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas KND's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to KND's ROE of -0.53%. Regarding short-term risk, MD is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check KND's competition here
MD vs TVTY Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas TVTY's P/E ratio is 19.06. In terms of profitability, MD's ROE is +0.20%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, MD is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check TVTY's competition here
MD vs DCGOW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas DCGOW's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, MD is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check DCGOW's competition here
MD vs NFH Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, NFH has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas NFH's P/E ratio is -19.75. In terms of profitability, MD's ROE is +0.20%, compared to NFH's ROE of -0.06%. Regarding short-term risk, MD is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check NFH's competition here
MD vs HNGR Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas HNGR's P/E ratio is 19.71. In terms of profitability, MD's ROE is +0.20%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, MD is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check HNGR's competition here
MD vs AFAM Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas AFAM's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, MD is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check AFAM's competition here
MD vs SLHGP Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, MD's ROE is +0.20%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, MD is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check SLHGP's competition here
MD vs TLMD Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas TLMD's P/E ratio is -1.60. In terms of profitability, MD's ROE is +0.20%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, MD is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check TLMD's competition here
MD vs SLHG Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas SLHG's P/E ratio is -1.48. In terms of profitability, MD's ROE is +0.20%, compared to SLHG's ROE of N/A. Regarding short-term risk, MD is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check SLHG's competition here
MD vs DVCR Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas DVCR's P/E ratio is 28.34. In terms of profitability, MD's ROE is +0.20%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, MD is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for MD.Check DVCR's competition here
MD vs ATIP-WT Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, MD is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check ATIP-WT's competition here
MD vs TLMDW Comparison June 2026
MD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MD stands at 1.8B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, MD is priced at $22.37, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MD currently has a P/E ratio of 10.86, whereas TLMDW's P/E ratio is N/A. In terms of profitability, MD's ROE is +0.20%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, MD is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for MD.Check TLMDW's competition here